Decentralized clinical trial specialist Curebase said today that it has secured $40 million in Series B funding. The lead investor in the round was Industry Ventures. Other investors contributing to the round include Acrew Capital, World Innovation Lab, Positive Sum, Gilead Sciences (Nasdaq:GILD) and existing investors GGV Capital, Bold Capital and Xfund. The San Francisco–based…